## SNPS: Synopsys, Inc. - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 9.8% in upper entry zone (4.0-10.0%), top 7% cross-sectional ranking. Short-term MRS_5 (1.5%) confirms momentum alignment. Outperforming sector by 8.6%. Caution: overbought RSI (71).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($446.14)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Investors SueWallSt as Synopsys, Inc. Faces Securities Fraud Allegations**
- Source: Fox 59 | 20251209T220852 | Neutral | Relevance: 99%
- A class action lawsuit has been filed against Synopsys, Inc. on behalf of investors who allegedly suffered financial losses due to securities fraud between December 4, 2024, and September 9, 2025. Levi & Korsinsky, LLP, which specializes in complex securities litigation, is representing the aggrieved shareholders and encourages affected investors to come forward.

**2. Pomerantz LLP Issues Important Reminder to Shareholders in Synopsys, Inc. of Class Action â€“ SNPS**
- Source: KFOR.com | 20251210T120917 | Neutral | Relevance: 99%
-  Pomerantz LLP has filed a class action lawsuit against Synopsys, Inc. (NASDAQ: SNPS) on behalf of shareholders. The lawsuit alleges securities fraud and other unlawful business practices, stemming from Synopsys's third-quarter 2025 financial results which showed underperformance in its "IP business" and a significant stock price drop. Shareholders who purchased Synopsys securities during the class period have until December 30, 2025, to seek appointment as Lead Plaintiff.

**3. SNPS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Synopsys, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: WANE 15 | 20251211T120901 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Synopsys, Inc. (NASDAQ: SNPS) on behalf of investors who purchased securities between December 4, 2024, and September 9, 2025. The lawsuit alleges that Synopsys made materially false and misleading statements regarding the financial impact of its increased focus on artificial intelligence customers on its Design IP business. Investors who suffered losses have until December 30, 2025, to request to be appointed as lead plaintiff.

**4. Synopsys, Inc. Securities Fraud Class Action Result of Undisclosed Financial Problems and 35% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSF**
- Source: GlobeNewswire | 20251210T040919 | Neutral | Relevance: 98%
-  Kahn Swick & Foti, LLC (KSF) is reminding investors of Synopsys, Inc. (SNPS) who suffered substantial losses to file lead plaintiff applications by December 30, 2025, in a securities class action lawsuit. This action stems from alleged undisclosed financial problems and a 35% stock decline after the company missed revenue guidance and reported a significant year-over-year net income decline in Q3 2025. Investors who purchased securities between December 4, 2024, and September 9, 2025, or acquired Synopsys common stock for Ansys shares, are encouraged to contact KSF for legal consultation.

**5. Synopsys Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts**
- Source: Benzinga | 20251210T070923 | Somewhat-Bullish | Relevance: 98%
-  Synopsys, Inc. (NASDAQ: SNPS) is preparing to release its Q4 earnings, with analysts expecting $2.88 earnings per share on $2.24 billion in revenue. The company recently expanded its partnership with NVIDIA (NASDAQ: NVDA). Several prominent analysts have updated their ratings and price targets for Synopsys ahead of the earnings call.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 5)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | JP Morgan | $650 | $600 | +8% |
| 2025-12-11 | Wells Fargo | $500 | $445 | +12% |
| 2025-12-11 | Keybanc | $600 | $575 | +4% |
| 2025-12-11 | B of A Securiti | $560 | $500 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | JP Morgan | main | Overweight |
| 2025-12-11 | Wells Fargo | main | Equal-Weight |
| 2025-12-11 | Keybanc | main | Overweight |
| 2025-12-11 | B of A Securiti | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.54M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (+20.7%)
- Blackrock Inc.: 8.2% (+18.5%)
- State Street Corpora: 4.7% (+20.6%)
- Capital World Invest: 4.0% (-3.7%)
- FMR, LLC: 3.1% (+47.5%)

### Key Risks

1. High beta (2.10) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 6.1x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Analyst target momentum: 5 raises (avg +8%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.11 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 31%). Revenue growth strong at 37% YoY. Insider buying signal ($0.5M), management confidence. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $91.0B |
| Beta | 1.00 |
| 52W Range | $365.74 - $651.73 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.11 |
| Forward P/E | 27.6 |
| Current P/E | 33.2 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 11.0% to 9.8% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 92nd percentile. MRS_5 at 1.5% confirms short-term momentum alignment. AM_20 at 12.0% shows strong absolute momentum above own 20MA. Outperforming sector by 8.6pp, stock-specific strength. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (8.47), confirming momentum. RSI overbought at 71, risk of mean reversion. Elevated volume (1.6x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 9.77% (CS: 93) | Strong |
| RSI_14 | 70.8 | Overbought |
| MACD Histogram | 8.47 | Bullish |
| vs SMA20 | 1.120x | Above |
| vs SMA50 | 1.091x | Above |
| vs SMA200 | 0.977x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $477.26
- **Stop Loss:** $446.14 (6.5% risk)
- **Target:** $523.94 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 44
- **Position Value:** $20,999.44
- **Portfolio %:** 21.00%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.75 | $3.39 | -9.5% |
| 2025Q2 | $3.40 | $3.67 | +8.0% |
| 2025Q1 | $2.79 | $3.03 | +8.6% |
| 2024Q4 | $3.30 | $3.40 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*